Abstract
The TGF-β signaling pathway is central to the control of diverse biological processes including cellular proliferation, cell survival, apoptosis, extracellular matrix deposition/remodeling, migration, invasion and immune regulation/inflammation. Given the pleiotropic effects of this cytokine, it comes as no surprise that numerous pathological conditions are associated with alterations in the TGF-β pathway, including chronic fibrosis, airway remodeling (asthma), cardiovascular disease and cancer. Thus, there are increasing efforts to develop reagents and therapeutic strategies to impair TGF-β signaling. Here we review several classes of inhibitors, including knockdown strategies aimed at signaling components of the TGF-β pathway, TGF-β neutralizing antibodies, TGF-β receptor extracellular domains that function as ligand traps and small molecule kinase inhibitors. Strategies with potential for application as anti-cancer therapeutics that have been evaluated in pre-clinical animal models will be discussed. TGF-β action is complex, shifting from a tumor suppressor to a promoter of tumor cell invasion and metastasis in several types of cancer. This raises important issues regarding not only the status of the TGF-β pathway in the individual patient but also the precise stage during disease progression that such inhibitors should be employed. Potential consequences of targeting the TGF-β pathway will also be considered.
Keywords: TGF-β Pathway, antagonists, ligand-traps, knock-down strategies, kinase inhibitors, targeted therapies, pre-clinical models, cancer
Anti-Cancer Agents in Medicinal Chemistry
Title: Targeting Aberrant TGF-β Signaling in Pre-Clinical Models of Cancer
Volume: 7 Issue: 5
Author(s): Anna Alexeyevna Mourskaia, Jason Jonathan Northey and Peter Michael Siegel
Affiliation:
Keywords: TGF-β Pathway, antagonists, ligand-traps, knock-down strategies, kinase inhibitors, targeted therapies, pre-clinical models, cancer
Abstract: The TGF-β signaling pathway is central to the control of diverse biological processes including cellular proliferation, cell survival, apoptosis, extracellular matrix deposition/remodeling, migration, invasion and immune regulation/inflammation. Given the pleiotropic effects of this cytokine, it comes as no surprise that numerous pathological conditions are associated with alterations in the TGF-β pathway, including chronic fibrosis, airway remodeling (asthma), cardiovascular disease and cancer. Thus, there are increasing efforts to develop reagents and therapeutic strategies to impair TGF-β signaling. Here we review several classes of inhibitors, including knockdown strategies aimed at signaling components of the TGF-β pathway, TGF-β neutralizing antibodies, TGF-β receptor extracellular domains that function as ligand traps and small molecule kinase inhibitors. Strategies with potential for application as anti-cancer therapeutics that have been evaluated in pre-clinical animal models will be discussed. TGF-β action is complex, shifting from a tumor suppressor to a promoter of tumor cell invasion and metastasis in several types of cancer. This raises important issues regarding not only the status of the TGF-β pathway in the individual patient but also the precise stage during disease progression that such inhibitors should be employed. Potential consequences of targeting the TGF-β pathway will also be considered.
Export Options
About this article
Cite this article as:
Mourskaia Alexeyevna Anna, Northey Jonathan Jason and Siegel Michael Peter, Targeting Aberrant TGF-β Signaling in Pre-Clinical Models of Cancer, Anti-Cancer Agents in Medicinal Chemistry 2007; 7 (5) . https://dx.doi.org/10.2174/187152007781668689
DOI https://dx.doi.org/10.2174/187152007781668689 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of T-Helper Cells in Atherosclerosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Spray-Dried Polymeric Nanoparticles for Pharmaceutics: A Review of Patents
Recent Patents on Drug Delivery & Formulation Application of dsRNA in Cancer Immunotherapy: Current Status and Future Trends
Anti-Cancer Agents in Medicinal Chemistry Anti-Tubercular Agents from <i>Glycyrrhiza</i> glabra
Current Topics in Medicinal Chemistry Inhibition of Mitogen-Activated Protein Kinases (MAPKs) as a Strategy to Prevent Intimal Hyperplasia Following Cardiovascular Interventions
Vascular Disease Prevention (Discontinued) Preface (Hot Topic: Pulmonary Inflammation Guest Editor: Momtchilo Russo)
Current Drug Targets - Inflammation & Allergy Current Advances and Therapeutic Potential of Agents Targeting Dipeptidyl Peptidases-IV, -II, 8/9 and Fibroblast Activation Protein
Current Topics in Medicinal Chemistry Narcolepsy in Adolescents: A Review and Three Case Reports
Adolescent Psychiatry Biotechnological Approaches for the Treatment of Inflammatory Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry New Drugs for Immune Targeting
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Contingency Management for Smoking Cessation: Where Do We Go from Here?
Current Drug Abuse Reviews Molecular Hybrids of N-Phthaloylglycyl Hydrazide and Hydrazinecarbothioamide with Anti-inflammatory and Anti-oxidant Activities
Current Organic Synthesis Potential Role of Rho Kinase Inhibitors in Combating Diabetes-Related Complications Including Diabetic Neuropathy-A Review
Current Diabetes Reviews Plant Coumestans: Recent Advances and Future Perspectives in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Optimized and Comparative Antioxidant Assays and Its Applications in Herbal and Synthetic Drug Analysis as an Antioxidants
Mini-Reviews in Medicinal Chemistry Adjudin - A Male Contraceptive with Other Biological Activities
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Small-Molecule Chemokine Receptor Antagonists: Potential Targets for Inflammatory and Allergic Disorders
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Bioactive Herbal Alkaloids as Anti-Infective Agents
Anti-Infective Agents Reducing Food Allergy: Is There Promise for Food Applications?
Current Pharmaceutical Design Drug Discovery in Enteroviral Infections
Infectious Disorders - Drug Targets